To investigate the possibility that HIV-1 replication in lymph nodes sustains the reservoir 45 during antiretroviral therapy (ART), we looked for evidence of viral replication in 5 donors after up 46 to 13 years of viral suppression. We characterized proviral populations in lymph nodes and 47 56 Antiretroviral therapy (ART) effectively prevents HIV-1 disease progression; however, low-57 level viremia persists during ART and typically rebounds to pre-therapy levels when treatment is 58 discontinued. Rebounding virus is not genetically divergent from pre-ART HIV-1 variants (1-3), 59 suggesting a stable viral reservoir during ART that is likely established prior to initiating treatment. 60
peripheral blood before and during ART, evaluated the levels of viral RNA expression in single 48 lymph node and blood cells, and characterized the proviral integration sites in paired lymph node 49 and blood samples. Proviruses with identical sequences, identical integration sites, and similar 50 levels of RNA expression were found in lymph nodes and blood samples collected during ART, 51 and no single sequence with significant divergence from the pretherapy population was detected 52
Introduction
To determine if the mechanisms that maintain HIV-1 proviruses in lymph nodes differ from 80 those in peripheral blood, and whether there is ongoing exchange of infected cells between these 81 compartments, we compared the proviral populations in lymph nodes and peripheral blood from 82 five participants whose levels of viremia were suppressed on ART (<40 copies/ml) for 1.8 to 12.9 83 years. We addressed the following questions related to the mechanisms that maintain the HIV-1 84 reservoir in lymph nodes during ART: 1) During long-term ART, are proviral populations in lymph 85 nodes divergent from pre-ART proviral populations in lymph nodes and peripheral blood? 2) Are 86
HIV-1 proviral populations divergent between paired lymph node and peripheral blood samples 87 collected after long-term ART? 3) Do proviral populations in lymph nodes change over time in a 88 manner characteristic of ongoing HIV-1 replication during ART? 4) Are the clonal populations of 89 infected cells that persist on ART different in lymph nodes compared to peripheral blood? 5) Do 90 more infected cells in lymph nodes contain HIV-1 RNA compared to those in peripheral blood? 6) 91
Are proviruses in lymph nodes expressed at higher levels than those in peripheral blood? 7) Are 92 the replication-competent proviruses in lymph nodes that are induced in viral outgrowth assays 93 divergent from pre-ART viral populations? 8) Is there a higher number of CD4+ T cells carrying 94 infectious, inducible proviruses in lymph nodes compared to peripheral blood during ART? 95
The results we obtained support the conclusion that HIV-1 infected cells persisting on 96 long-term ART are well mixed between the peripheral blood and lymph nodes and that the HIV-1 97 reservoir is sustained in the lymph nodes by proliferation of cells that were infected prior to ART 98 and not by ongoing cycles of viral replication during ART.
Results 100

Donor characteristics 101
Samples from five HIV-1 infected participants from the San Francisco SCOPE cohort 102 (NCT00187512) (23) (Table S1) were investigated for evidence of ongoing HIV-1 replication, as 103 assessed by evolution of sections of the viral genome in peripheral blood and lymph nodes during 104 ART. In these donors, viremia was well-suppressed on ART (<40 HIV-1 RNA copies/ml plasma) 105 for 1.8 to 12.9 years. Two participants, 3720 and 2661, achieved viral suppression in early 106 infection (<1 year and 0.3 years after the approximate date of transmission). The low pretreatment 107 genetic diversity of the HIV-1 populations in these donors provided a sensitive probe for the 108 detection of viral divergence in the peripheral blood or lymph nodes for periods of 1.8 years and 109 12.9 years, respectively. Donor 2661 had one brief ART interruption after 4.7 years, was quickly 110 re-suppressed, and subsequently maintained continuous suppression of viremia on ART for 111 another 12.9 years. The other three participants initiated ART in chronic infection (2.0 to >22 112 years after the approximate date of transmission). 113
All donors had HIV-1 subtype B infection except donor 3720 who was infected by subtype 114 C. With one exception, no participant had detectable mutations conferring resistance to current 115 therapy in any samples studied. Donor 2669 had a history of mono-and/or dual-therapy, and, 116 consequently, acquired reverse transcriptase inhibitor drug resistance mutations prior to 117 achieving continuous viral suppression for 5.5 years following the addition of dolutegravir to his 118 treatment regimen. Single-genome sequencing (SGS) of the integrase coding region in peripheral 119 blood mononuclear cells (PBMC) and lymph node mononuclear cells (LNMC) did not detect 120 mutations that would contribute to dolutegravir resistance (92 single-genome DNA sequences 121 obtained from PBMC and 115 from LNMC). 122
To compare the evolution of HIV-1 between the different locations, pre-ART plasma and/or 123 paired samples from contralateral inguinal lymph nodes, enabling comparison of the proviral 126 populations in the two nodes. After completing this study, one donor interrupted ART, and a 127 plasma sample was obtained 14 days after discontinuation, allowing the rebounding plasma viral 128 RNA population to be compared to pre-ART RNA sequence variants in plasma, to the pre-ART 129 DNA and cell-associated RNA variants in peripheral blood, and to the on-ART DNA and cell-130 associated RNA variants in peripheral blood and lymph nodes. A detailed timeline of participant 131 sampling is shown in Table S2 . 132
133
No evidence for HIV-1 evolution during ART in peripheral blood 134
Previous studies have demonstrated the absence of detectable HIV-1 evolution in the 135 peripheral blood during ART (3, 6, 9, 10) . Because HIV-1 replication is error prone, this result 136
shows that there is, at most, only very limited HIV-1 replication in blood. To ensure that ART fully 137 suppressed viral replication in the peripheral blood of this set of donors, we performed SGS of 138 the P6-PR-RT region derived from virus in the plasma or viral DNA in PBMC collected prior to 139 ART and after 1.8 to 12.9 years of continuous viral suppression ( Figure 1 ). We also performed 140 SGS on the full-length env gene in proviruses from pre-and on-ART PBMC samples from donors 141 1683 and 1079 ( Figure S1 ). Because evolution would be a consequence of ongoing viral 142 replication, we looked for evidence of viral evolution on ART. Evolution of the proviral sequences 143 would cause: 1) increasing genetic diversity measured by average pairwise distance (APD), 2) 144 increasing genetic divergence of individual sequences from the starting population over time, as 145 shown by a statistically significant (p<0.001) negative test for panmixia comparing the two time 146 points (24), and 3) emergence of new viral variants, observable by increasing average and 147 individual root-to-tip distances over time on maximum-likelihood phylogenetic trees (Figure 1 , S1). 148
There was no evidence of HIV-1 evolution characteristic of ongoing cycles of viral 149 replication detected (in either P6-PR-RT or env) in peripheral blood from any of the four individuals 150 we studied by any of these analytical tools. Two donors ( Figure 1A , B) were treated in early 151 infection and the HIV-1 populations did not shift from the apparent pre-ART founder viruses over 152 1.8 and 12.9 years of continuous treatment (probability of panmixia = 0.1 and 0.4, respectively). 153
HIV-1 sequences with APOBEC-mediated G to A hypermutation, which are commonly seen in 154 individuals on ART (25), as well as any other sequences containing stop codons, were excluded 155 from these and all subsequent analyses. In donor 1683 ( Figures 1C and S1A) , the diversity in the 156 proviral population decreased during ART in both P6-PR-RT and env (0.5% to 0.1%, p<0.0001 157 and 1.3% to 0.6%, p<0.0001). In this donor, the HIV-1 population became dominated by a single 158 clonal sequence that was already present in the pre-ART population 5.4 years prior and may have 159 been directly derived from the original founder virus. The increased proportion of this clonal 160 variant also resulted in divergent (non-panmictic) proviral populations prior to and during ART in 161 P6-PR-RT (p=5x10 -6 ), a difference that disappeared when the identical sequences were collapsed 162 to single variants (p=0.7), as was done for all the panmixia analyses shown in the figures. This 163 result implies that the apparent shift in the population during ART was due to clonal proliferation 164 of infected cells, rather than emergence of new variants from ongoing replication. The root-to-tip 165 analysis also showed a potential loss of P6-PR-RT sequences on longer branches from the pre-166 ART population (slope = -2.0x10 -5 ). Similar results were obtained from analyses of the same two 167 genomic regions in peripheral blood from donor 1079 ( Figure 1D and S1B), treated in chronic 168 infection, despite the absence of prominent clonal variants in these samples after 11.4 years on 169
ART. 170
As in previous studies (3, 6, 9, 10) , comparative analyses of single-genome sequences 171 obtained before therapy and after up to 13 years of suppressive ART provided no evidence for 172 ongoing replication of HIV-1 in peripheral blood. On the contrary, all changes in the genetic 173 structure of proviral DNA populations can be attributed to clonal proliferation of cells containing 174 proviruses laid down prior to treatment initiation or the loss of variants during ART. 175
176
No evidence for HIV-1 evolution during ART in lymph nodes
It has been suggested that the drugs used in ART do not optimally penetrate lymph nodes 178 (19, 22) , permitting persistent HIV-1 replication in lymph nodes (16, 20) . If significant levels of 179 viral replication occur in the lymph nodes during ART, then the newly emergent viral variants 180 produced by the accumulation of reverse transcriptase errors would have to be sequestered in 181 the lymph nodes, because they are not detected in the peripheral blood (as shown above). This 182 argument predicts significant compartmentalization of HIV-1 DNA between the infected 183 mononuclear cells in the lymph nodes and those in the peripheral blood. To address the possibility 184 that HIV-1 infected cells are compartmentalized between the lymph nodes and peripheral blood, 185
and that viral replication continues during ART at levels that sustain the HIV-1 reservoir in the 186 lymph nodes as previously claimed (16), we compared proviral sequences of P6-PR-RT ( Figure  187 2) and env ( Figure S2 ) from the lymph nodes and peripheral blood of the donors in this study. 188
The results of this analysis yielded no evidence of compartmentalization in any of the 189 donors when proviral sequences from the paired peripheral blood and lymph node samples were 190 compared, in aggregate or individually, using the same three analytical tools as above ( Figure 2 , 191 S2). These results (in detail below) indicate that infected cells are well-mixed between the two 192 compartments, and imply the absence of significant viral replication in lymph nodes, just as in 193 peripheral blood, during suppressive ART. Neighbor joining phylogenetic analyses of P6-PR-RT 194 sequences from the two donors who were treated in early infection (Figures 2A-B ) showed, in 195 each case, a prominent group of identical sequences in the lymph nodes that was identical to the 196 presumed founder viruses (the most common variants observed in the peripheral blood prior to 197 ART), suggesting that no detectable sequence divergence occurred in the lymph nodes over 1.8 198 or 12.9 years of viral suppression on ART in these two individuals (there were not enough cells 199 available from these donors to sequence env). After sampling over half of the infected cells in an 200 entire lymph node from donor 2661, we found only a few P6-PR-RT variants to be 1-2 nucleotides 201 different from the sequence of the presumed founder virus and these had not diverged from the 202 plasma virus in the pre-ART sample (APD: p=0.08, panmixia: p=0.2). Though the positive branch 203 length correlation coefficient indicated a significant difference in branch lengths between lymph 204 node and peripheral blood (r=0.26; p=0.0005), when identical sequences were converted into 205 single variants this difference disappeared (r=-0.065; p=0.6), suggesting that the difference was 206 due to the fact that an identical variant was sampled at a disproportionately higher level in the 207 peripheral blood than in lymph nodes or that an expanded clone carrying this variant is not equal 208 in size across the two locations. As in the blood, the only noticeably divergent sequences in the 209 lymph nodes were G to A hypermutants. 210
A lack of compartmentalization between peripheral blood and lymph nodes was also 211 sequences in the lymph node from this donor (from 0.1 to 0.3%, p=0.04); however, as in donor 217 2661, this difference can be attributed to the disproportionate representation, between the two 218 locations, of a major clonal variant, a difference that likely arises from the physiology of cells in 219 those particular locations (such as expression of homing signals or responsiveness to antigen 220 (14)) rather than a property of the provirus itself. When identical sequences were condensed into 221 single variants, the diversity of the populations in the peripheral blood and lymph nodes was not 222 statistically different (p=0.7). Differences in the number of rakes of identical sequences were 223 observed between P6-PR-RT and env, particularly in PID 1683 (Table 2 ). Such differences likely 224 reflect the more rapid accumulation of diversity in env compared to pol and, possibly, the different 225 selection pressures on env vs. pol including the humoral immune response and/or cell tropism. 226
Identical sequences common to both peripheral blood and lymph nodes (indicated with black 227 arrows in the figures) were found in the donors who initiated ART in chronic infection; these 228 identical sequences likely resulted from clonal expansion of cells infected prior to the initiation of 229 ART. If so, these data imply trafficking of clonally expanded cells between the two compartments. 230
The presence of indistinguishable HIV-1 populations in paired peripheral blood and lymph node 231 samples collected during ART suggests, with our level of sampling (see discussion), that ongoing 232
HIV-1 replication in lymph nodes is likely insufficient to sustain the HIV-1 reservoir during 233
treatment. 234
In addition to seeking evidence for compartmentalization between lymph nodes and 235 peripheral blood, we also investigated the possibility of compartmentalization between two 236 separate lymph nodes from the same donor at the same time point ( Figure S3 ). LNMC were 237 collected from contralateral inguinal lymph nodes of two donors and proviral P6-PR-RT 238 sequences were obtained. In both donors, we found the HIV-1 populations in the paired lymph 239 nodes to be well-mixed, showing no evidence for viral compartmentalization between nodes by 240 any metric (for donors 1079 and 2669, respectively: APD: p=0.8 and 0.3, panmixia: p=0.3 and 241 0.7, branch length correlation: p=0.05 and 0.7). These data imply that infected cells traffic between 242 peripheral blood and lymph nodes and provide additional evidence that ART effectively blocks 243
HIV-1 replication in lymph nodes as well as peripheral blood to levels that are not detectable with 244 our level of sampling by SGS. 245
To further address the question of ongoing viral replication in lymph nodes during ART, 246
we pooled the proviral sequences obtained from the paired lymph node samples in each donor 247 and compared those sequences to proviral sequences obtained from a lymph node one year prior 248 (during ART) or from a lymph node collected prior to ART initiation ( Figure 3 ). Using the analytical 249 tools described above, we observed no change in the diversity or divergence of the HIV-1 proviral 250 populations in the longitudinal lymph node samples (for donors 3720, 1079, and 2669, 251 respectively: APD comparison: p=0.8, 0.9, and 0.9, panmixia: p=0.6, 0.8, and 0.9, and branch 252 length correlation: p=0.9, 0.9, and 0.9). The lack of any detectable change in the proviral 253 populations in longitudinal lymph nodes during years of therapy again shows that ART is effective 254 at blocking viral replication in the lymph nodes. 255
HIV-1 Integration site comparison of clonal populations in lymph nodes and peripheral blood 257
The sites at which HIV-1 proviruses are integrated can be used to monitor the clonal 258 expansion of infected cells (11) . Because HIV-1 integrates almost randomly into many sites in the 259 human genome, finding multiple cells with exactly the same sites of integration is very strong 260 evidence that these cells are descendants from a single infected cell. By this principle, integration 261 site analysis can be used to monitor the trafficking and compartmentalization of populations of 262
HIV-1 infected cells. Thus, when infected cells at two different locations have identical integration 263 sites, they must be members of a clone derived from the same infected cell, and cells from that 264 clone must have trafficked between the two locations. We used the integration sites assay to 265 determine whether the same expanded clonal populations were present in lymph node and 266 peripheral blood (Table 1) . From each donor, we obtained 143-247 integration sites from the 267 peripheral blood samples and 63-579 integration sites from the lymph nodes [full set of integration 268 sites deposited in the Retroviral Integration Sites Database (RID), accessible by Pubmed ID at 269 (https://rid.ncifcrf.gov/)]. Clones were defined as proviruses with identical integration sites that 270 were detected at least once in each of two different locations or samples regardless of ART status, 271 in two or more different DNA fragments in the same location or sample during ART, or three or 272 more times prior to ART (26) . Although the presence of two identical integration sites is indicative 273 of cell division, we define clones in pre-therapy conservatively as requiring three detection events 274 because dividing cells could die before establishing an expanded cell clone. In the three ART 275 treated donors in which the numbers of infected cells were sufficient for integration site analyses 276 (1683, 1079, and 2669), common clones were detected between lymph nodes and peripheral 277 blood. Of note, in the combined dataset, we found evidence for selection for integrations in the 278 BACH2 (p=3.0x10 -7 ), MKL1 (p=0.010), and STAT5B genes (p=3.5x10 -4 ) as previously reported 279 (11, 13) . Overall, in these three donors, the clonal populations were not significantly different between the lymph nodes and peripheral blood (p=0.1), confirming the absence of detectable 281 compartmentalization of infected cells between those locations (Table 2) . 282 283 Expression of HIV-1 proviruses in peripheral blood and lymph nodes prior to and on ART 284
Our analysis of proviral populations showed no evidence of ongoing HIV-1 replication in, 285 or compartmentalization between, peripheral blood and lymph nodes. In a further study, we 286 determined the fraction of infected cells with unspliced HIV-1 RNA (monitoring P6-PR-RT) and 287 the levels of proviral expression in single cells in each location. Using our cell-associated RNA 288 and DNA single-genome sequencing (CARD-SGS) assay, which can detect a single HIV-1 P6-289 PR-RT RNA sequence in a single infected cell (27), we compared the level of unspliced viral RNA 290 in single cells obtained from paired peripheral blood and lymph node samples (Table 3, Table S3 ) 291
( Figure 4 , 5, S4). While our previous work showed that there are single cells with high levels of 292
HIV-1 RNA in the peripheral blood of untreated individuals, cells with similarly high levels of viral 293 RNA were not detected in the peripheral blood of patients on ART (27) . The observation of cells 294 containing high levels of viral RNA (which may be on the viral replication pathway) in lymph nodes 295 during ART would provide support for the proposal that there are significant levels of ongoing 296 replication in the lymph nodes. Although cells expressing high levels of HIV-1 RNA can be seen 297 in in situ hybridization assays on lymph nodes of HIV-infected individuals on ART (20, 28, 29) , 298 they are much more rare than in untreated individuals, and may well reflect activation of HIV-1 299 expression in descendants of cells infected prior to ART initiation. The low-level persistent viremia 300 seen in most suppressed patients implies that highly-expressing cells must exist, albeit at 301 numbers averaging about 10,000-fold lower than before treatment initiation (27) . 302
We found no overall difference in the fraction of infected cells that contained viral RNA in 303 lymph nodes compared to peripheral blood during ART (median 13% in LNMC vs. median 8% in 304 PBMC) (p=0.13) or in the levels of proviral expression within single cells between the lymph nodes 305
and peripheral blood (median = 1 RNA molecule/expressing cell in both). In donor 3720, we 306 detected a few cells in the peripheral blood and lymph node with high levels of viral RNA 307 (containing >20 HIV-1 RNA molecules) prior to ART, while no such cells were observed in a 308 sample taken after 1.8 years on ART ( Figure 5A , cells with high viral RNA levels indicated with 309 blue arrows; pre-ART data from lymph nodes, including 3 cells with high HIV-1 RNA levels, not 310 shown). Similarly, in donor 1683, one cell with a high level of viral RNA was identified in the 311 peripheral blood prior to ART, and none was found after 5.4 years on ART in either peripheral 312 blood or lymph nodes ( Figure 5B , indicated with blue arrow). In donor 1079, no cells with high 313 levels of viral RNA were detected at either time point ( Figure 5C , 353 HIV-1 infected cells assayed 314 for HIV-1 RNA from pre-ART and 1315 on ART). Although a pre-ART sample was not available 315 for donor 2669, we did detect one LMNC during ART with 28 molecules of HIV-1 RNA (Figure  316 S4C). These data suggest that cells that have high levels of viral RNA are rare and, as expected 317
for productive infection, may be preferentially eliminated. It is also likely that latently-infected cells, 318 or cells with very low levels of HIV-1 expression, are not eliminated and, therefore, accumulate 319 over the duration of infection, possibly explaining why high-expressing cells were detected before 320 ART initiation in donors 3720 and 1683 (who were still rather early in infection) and not in 1079 321
(who had been infected for more than 4 years at the time of ART initiation), although a larger 322 study would be required to investigate this possibility. 323
As reported previously (27), we also found RNAs with identical P6-PR-RT sequences in 324 different single cells, suggesting that clonally proliferating populations of infected cells include 325 ones with proviruses that are actively expressing low levels of HIV-1 RNA. While it is possible that 326 such cells are the source of viral rebound when ART is interrupted, it is more likely that there are 327 always very rare highly expressing cells, as can be seen by in situ hybridization (20, 28, 29) that 328
give rise to persistent and rebound viremia and, in some cases, are the source of outgrowth in 329 viral outgrowth assays. In donor 3720, the viral outgrowth assay (30) identified multiple sequences 330 obtained from pre-ART as replication competent ( Figure 1A , 2A, 3A indicated with red arrows). 331
Two of the viral sequences obtained in viral outgrowth assays matched RNA sequences obtained 332 from multiple PBMC prior to ART and from multiple PBMC and LNMC obtained after 1.8 years on 333 ART ( Figure 5A , S4A, indicated with red arrows). In donor 1079, a treatment interruption revealed 334 two major rebound variants in the consequent viral rebound, one of which matched a set of six 335 lymph node-derived cell-associated RNA sequences obtained from a single cell after 11.4 years 336 on-ART ( Figure 4B , indicated with yellow arrow). This observation suggests that rebound viremia 337 resulted from a clone of infected cells, some of which were actively transcribing HIV-1 RNA prior 338 to ART interruption, as previously reported (2). The other rebounding variant matched a single 339 proviral sequence obtained from the peripheral blood during ART (data not shown but sequence 340 submitted to GenBank, accession #MK147615). Thus, persistent, rebound, and rescued virus can 341
have the same genetic properties as the proviral DNA described above, showing no evidence of 342 ongoing replication or evolution, but strong evidence for clonal expansion of the cells responsible 343 for it. 344
In estimating the fraction of infected cells that contain HIV-1 P6-PR-RT RNA, our 345 measurements of the number of HIV-1 infected cells were based on a particular region of the 346 genome, in the pol gene (31) ( Table 3 ). To ensure that the region of the viral genome we analyzed 347 did not affect our conclusions, we also used primers and probes in the LTR (R-U5) and in the gag 348 gene (Table S3 ). Though quantification by these methods resulted in varying counts of infected 349 cells (likely due to some proviruses having large internal deletions or variants with mismatches to 350 the primers or probes), our estimates for the fractions of infected cells with HIV-1 P6-PR-RT RNA 351
were not significantly different between the peripheral blood and lymph nodes, regardless of the 352 genomic region used to detect proviral sequences (p=0.4 for LTR and p=0.7 for gag). Because 353 there are more CD4+ T cells in lymph nodes of some donors, and more infected cells in the lymph 354 nodes than in the peripheral blood, the overall number of HIV-1 RNA molecules we detected could 355 be higher in lymph nodes than in peripheral blood, as previously reported (20, 28). However, when 356 the levels of HIV-1 RNA in single infected cells were compared, we found no difference between 357 the cells from peripheral blood and lymph nodes during long-term ART. These findings 358 demonstrate that lymph nodes cells containing high levels of HIV-1 RNA collected from HIV-359 infected individuals on ART, such as those detected here and previously using in situ hybridization 360 assays (27-29), more likely reflect activation of HIV-1 expression in descendants of cells infected 361 prior to ART initiation than from cells infected from ongoing cycles of viral replication on ART. 362
363
No single proviral sequences on ART deviate from those in pre-ART 364
Our results clearly show that there is no detectable evolution of the bulk population in 365 either peripheral blood or lymph nodes for almost 13 years of suppressive ART. However, it 366 remains possible that a fraction of the proviral DNA population may have arisen by low-level 367 ongoing replication and that these sequences may not have been visible in analyses of the 368 population as a whole. Such variants would only be visible in the populations when analyzed 369 individually, as distinct outliers in the overall distribution of a diversity metric. To test for the 370 presence of such variants in the combined patient data, we normalized the root-to-tip distances 371 of all HIV-1 RNA or DNA sequences from pre-ART in each patient, when available, and divided 372 the results into bins, yielding a histogram centered around 0, as shown in Figure 6 (the red bar 373 graph). We then did the same analysis with the P6-PR-RT proviral sequences from the on-ART 374 peripheral blood and lymph node samples, normalizing individual distances to the respective 375 donor's pre-ART data, as shown in Figure 6 (grey and blue graphs, respectively). Thus 376 normalized, all patient data could be aggregated, allowing visualization of evolution of the 377 peripheral blood and lymph node populations overall, as well as sensitive detection of small 378 subpopulations that might be evolving separately from the bulk population. Analyses were 379 performed both on total sequences (left panels) and with groups of identical sequences collapsed 380 to remove the effects of clonal expansion (right panels). 381
Consistent with our previous analyses, the pre-ART and on-ART datasets yielded very 382 similar histograms, despite the samples being drawn from different anatomical locations and 383 separated by very long times. In the plots, any single sequence with a genetic distance of more than two standard deviations from the mean of the pre-ART sequence distribution would be 385 revealed as a significant outlier. Since we examined a total of about 125 sequences in each set, 386
we expected about 5% of the 122 PBMC or 129 LNMC sequences to be between 2 and 3 standard 387 deviations from the mean by chance, and none to be greater than 3. As the figure shows, the 388 number of such outlier sequences is actually less than the 6 sequences expected (0/122 total 389 sequences in the on-ART PBMC and 1/129 sequences in the on-ART LNMC) and very similar to 390 the frequency of such outliers in the pre-ART data. Given that HIV-1 genomes accumulate 391 mutations at about 1% per year in untreated patients (32) and one standard deviation in this 392 analysis corresponds to a genetic distance of between 0.08 and 0.9% from the root in these 393 donors, 3 standard deviations represents a very low bar based on the time between ART initiation 394 and the on-ART sampling, yet not a single provirus in 251 studied in the two tissues was able to 395 cross it. Thus, if there is ongoing replication, it can only involve, at most, 0.4% (upper bound of 396 95% CI = 1.2%) of the virus population in either blood or lymph nodes in ART-suppressed 397 patients.
Discussion 399
The question of whether ongoing viral replication sustains the HIV-1 reservoir during ART 400 has important implications for the design of curative interventions. Some have concluded that viral 401 replication in lymph nodes continues at levels that maintain the HIV-1 reservoir (16), and others 402 have claimed that viral replication may persist during ART, but in only a small subset of cells (20, 403 33). If HIV-1 replication persists on ART to the extent necessary to maintain the viral reservoir, 404 then the accumulation of new proviral mutations would be apparent after long-term ART. The 405 acquisition of new mutations would be especially evident in patients who initiated treatment in 406 early infection with a homogeneous virus population, such as donor 2661. In this donor, the 407 number of HIV-1 infected cells that persisted on ART was small compared to the individuals who 408 initiated ART in chronic infection, consistent with previous reports (34-37). As a result, all 150 409 million LNMC obtained from an entire lymph node were investigated for HIV-1 DNA or RNA. We 410 found that <600 infected cells persisted in the lymph node from this individual after almost 13 411 years on ART and <13% had unspliced HIV-1 RNA. Extrapolating this finding to the ~500-700 412 lymph nodes in the body, we can estimate that about 300,000-420,000 HIV-1 infected LNMC 413 persisted in this individual and about 39,000-55,000 had unspliced HIV-1 RNA. In contrast, the 414 donors who initiated ART in chronic infection and had been sustained on ART for a shorter 415 duration (about 1-5 years), according to our calculations, had as many as 175 million infected 416 LMNC in the entire body and as many as 22.8 million with unspliced HIV-1 RNA, 456,000 of which 417 may be "high-expressers". In total, we examined 251 lymph node and peripheral blood proviral-418 derived sequences from the donors who had pre-ART sampling and we failed to detect a single 419 provirus with a significant number of new mutations in either location in any of the donors. Thus, 420
if there is a fraction of the proviral population in either lymph node or peripheral blood representing 421 virus generated by ongoing replication, it must be very small. With our level of sampling, we can 422 report with 95% confidence that, if there is a replicating population, it is <1.2% of the total HIV-1 423 infected cells that persist on ART. Additionally, as viral RNA+ cells do not necessarily indicate 424 replication competency, <1.2% is a highly conservative estimate of the upper bound of a potential 425 replicating pool (25, 38) . 426
By contrast, the clonal proliferation of infected cells that contain replication-competent 427 proviruses can generate large pools of infected cells, some of which persist during long-term ART 428 (14, (39) (40) (41) . Our integration site assay data shows that clonal populations of infected cells that 429 are detectable after long-term ART in the peripheral blood and lymph nodes are not significantly 430 different and provides support for the conclusion that cell proliferation is likely to be the most 431 important mechanism that maintains the persistent viral DNA in blood and lymph nodes. These 432 data, taken together with the finding that the HIV-1 populations in peripheral blood and lymph 433 nodes are not genetically divergent and that infected cells in those locations contain similar levels 434 of viral RNA, show that this process is not different in these compartments. Importantly, these 435 data also show that infected cells are trafficked between the blood and the lymph nodes, as well 436 as between lymph nodes. This lack of compartmentalization further implies that ongoing cycles 437 of viral replication during ART do not persist in lymph nodes at a level that sustains the HIV-1 438 reservoir. Our findings support the conclusion that the viral DNA reservoir is maintained largely 439 or entirely by clonal proliferation of cells that were infected prior to initiating ART and that this 440 mechanism is important in both the peripheral blood and the lymph nodes. In sum, our results 441 refute the idea that development of new antiretroviral drugs (with improved targeting to lymph 442 nodes, for example) will be of value towards achieving a cure of HIV-1 infection. The very low 443 frequency of virus producing cells detectable by in situ PCR assays (20, 28, 29) , may be important 444 biologically for other reasons not addressed in this study, but our results imply that they are more 445 likely to be due to expression of rare proviruses in descendants of cells infected prior to therapy 446 than from ongoing viral replication. Likewise, the low number of high-expressing cells, though 447 likely to be the source of persistent viremia on ART and rebound viremia after stopping ART, is 
Participant cohort and sample collection 457
Samples from the five HIV-1 infected participants were obtained from the San Francisco 458 SCOPE cohort (NCT00187512) (23) ( Table S1 ). PBMC were separated with Ficoll and 459 resuspended in FBS with 10% DMSO. To disaggregate LNMC from lymph node biopsies, excess 460 fat was trimmed and the node was minced and strained on 70 and 40 micron nylon cell strainers. 461
Samples were shipped on dry ice and stored in liquid nitrogen until processed. 462 463
Sequence data availability 464
All sequence data are available on GenBank at accession numbers MK145079-465 MK148700. 466
467
HIV-1 quantification 468
HIV-1 DNA levels were determined using the integrase cell-associated DNA assay (31) or 469 using a droplet digital PCR (ddPCR) assay (42). For ddPCR, HIV-1 DNA copies per million cells 470
were measured in triplicate with a duplexed ddPCR assay measuring the amount of DNA 471 corresponding to HIV-1 gag (43), pol, and the RU5 region of the HIV-1 LTR. The amount of cellular 472 DNA was measured by CCR5 quantitation. The RU5 region of the HIV-1 LTR was amplified using 473 the following primers: RU5-F-5'-CTTAAGCCTCAATAAAGCTTGCC-3', RU5-R-5'-474 GGATCTCTAGTTACCAGAGTC-3', and RU5-Probe (Hex Zen)-5'-475 AGTAGTGTGTGCCCGTCTG-3'. Prior to amplification, DNA was extracted as in (31) and 476 randomly sheared with a Branson ultrasonic cup horn sonifier (Emerson) at 60% amplification in 477 pulse mode for 5 seconds. This step was repeated 3 times. Samples were then heated to 100 o C 478 for 15 minutes and snap cooled on ice. A 20µl PCR mastermix was made which gave a final concentration of 1x ddPCR Supermix for Probes (BioRad, USA), 750nM forward and reverse 480 primers, 250µM probe and 5µl DNA template. End-point PCR was performed with the following 481 conditions: 95 o C for 10 minutes, then 40 cycles of 94 o C for 30 seconds, 55 o C for 1 minute with a 482 ramp rate of 2 o C/second, followed by a final 98 o C for 10 minutes. After the reactions were 483 completed the samples were held at 12 o C. Reactions were then read on the QX200 Droplet 484
Reader (Bio-Rad, USA) and were analyzed using the Quantasoft software version 1.7.4 (Bio-Rad, 485 USA) with a user defined threshold. Averaged triplicate HIV DNA measurements were normalized 486 to one million PBMCs using concurrent triplicate CCR5 measurements. 487
488
Cell-associated RNA and DNA single-genome sequencing assay (CARD-SGS) 489 CARD-SGS was performed on the P6-PR-RT region of HIV-1 as previously described 490 (27). In brief, CARD-SGS is performed by diluting cells to near the endpoint for those with HIV-1 491 unspliced RNA and performing single-genome sequencing on reverse transcribed RNA. Using 492 single ACH2 cells, we previously showed that our method can detect a single HIV-1 P6-PR-RT 493 RNA molecule in a single cell (26). Because the reverse transcription step is known to introduce 494 errors at a rate of about 10 -4 per sequenced nucleotide of viral cDNA sequences (44), single RT-495 PCR variants that differed by a single nucleotide from a group of 5 or more identical sequences 496 within the same aliquot were counted with the majority. HIV-1 proviral SGS was performed on full-497 length env as previously described (45). 498 SGS of the full-length integrase coding region was carried out on PBMC cell-associated 499 DNA using the same PCR parameters as those described for P6-PR-RT (46) but using different 500 PCR primers: IntF1-5'-CATCTAGCTTTGCAGGATTCG-3' and IntR1-5'-501
CTGACCCAAATGCCAGTCTC-3'
and for nested PCR IntF2-5'-502 GGAAAAGGTCTACCTGGCATG-3' and IntR2-5'-TCTCCTGTATGCAGACCCCA-3'. Sequences 503 were aligned using ClustalW and all sequences that would clearly render the virus defective for 504 replication (stop codons within the coding region) were omitted from downstream analyses. 505
Population genetic diversity was calculated as average pairwise p-distance (APD) using MEGA 506 (www.megasoftware.net). Neighbor joining trees were constructed using MEGA and rooted on 507 consensus B or C as appropriate. 508
509
Integration sites assay (ISA) 510 ISA was performed as previous described (11) using patient-specific primers to the 5' and 511 3' LTRs. The full set of integration sites obtained were submitted to the Retroviral Integration Sites 512 Database (https://rid.ncifcrf.gov/) and can be accessed using the Pubmed ID for this paper. 
Signed Relative Deviation Analysis of Single Proviruses 548
Root-to-tip distances from patient ML trees containing all pre-ART sequences, pre-ART 549 sequences with identical sequences collapsed to a single variant, all on-ART proviral sequences 550 from PBMC and LNMC, and on ART proviral sequences from PBMC and LNMC with identical 551 sequences collapsed to a single variant were generated by phyML as described above. 552
Normalization was done by taking the average and standard deviation of root-to-tip distances 553 from the pre-ART sequence data. Signed relative standard deviations (sRSD) was then calculated 554
for each sequence i in each patient. The sRSD were then plotted as 555 histograms, as shown in Figure 6 . The upper limit of the confidence interval was determined by 556 the "rule of three" for an unseen event (47) . 557 558
Statistics 559
Implementation of the Hudson test for geographic subdivision-a test for panmixia-was 560 run using an in-house program and a significance cutoff of <10 -3 was applied to account for 561 multiple comparisons (24, 48) . Maximum likelihood (ML) trees were generated using the best fit 562 model from the Smart model selection and estimated in PhyML (49, 50) . Trees were rooted 563 against consensus HIV-1 subtype B or C sequences as appropriate. Root-to-tip distances were 564 plotted against the time of sample collection and evaluated via F-test on the resulting linear 565 regression (units for root-to-tip are substitutions/year). Branch length correlation coefficients for 566 compartmentalization were determined calculated as described in . Differences in APD were tested as described previously (6). Other standard 568 statistical analyses and summary statistics were done in R version 3.3.1. and are noted in figure  569 legends. In-house programs for the test for panmixia (java), root to tip analysis (python3), and 570 branch length tree correlation coefficient (python3) are available online at 571 www.github.com/michaelbale. 572 573
Study approval 574
Samples from the five HIV-1 infected participants were obtained from the San Francisco 575 SCOPE cohort (NCT00187512) (23) ( Table S1 ) and studies were approved by the internal review 576 board of the University of California San Francisco. Written informed consent was received from 577 the participants prior to inclusion in the study. 578 , EPB41, PIBF1, FLOT1 DNAJC16, ARHGAP25, MIDN, LOC100505746, ASH1L, KDM2A, NUMA1, STAT5B, ARHGAP33, IFNAR2, FBXL17, TTF1, CCP110, XPO6, TRPV3, MARCH14, AP3D1, ACAP2, ABHD16A, RPS10-NUDT3, RAB39B 0.1 a Integration sites assay (11) b Clonal integration sites were identified ≥2 times in a single location or at least once in both locations c Wilcoxon Signed Rank test to determine if differences in clonal detection is within sampling error Divergence was measured by a test for panmixia (to correct for multiple comparisons, populations are considered to be statistically different when the probability of panmixia is less than 0.001).
Red arrows indicate sequences matching virus obtained in a viral outgrowth assay (30). Root-totip distances were measured using maximum likelihood trees, and the slopes of the root-to-tip distances over time were calculated by linear regression (units for slopes are substitutions/year).
In cases where the slope was positive, an F-test was used to determine if the root-to-tip slopes were significantly different from zero. A is rooted on the HIV-1 subtype C consensus sequence, Neighbor joining trees were constructed from single-genome P6-PR-RT proviral sequences obtained from LNMC at two time points: the first prior to ART initiation or after 11.4 or 4.3 years on ART (dark blue triangles) and the second approximately one year later (light blue triangles).
Diversity, divergence, and root-to-tip distances were measured as described in the legend to 
